Related Experiment Video

Updated: Jan 9, 2026

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
13:18

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

Published on: June 28, 2013

22.0K

Pediatric Idiopathic Cardiomyopathy: Challenges in Etiology and Need for Targeted Therapy

Meaunique Pollock1, William H Frishman1,2

  • 1New York Medical College, Valhalla, NY.

Cardiology in Review
|December 10, 2025
PubMed

Insights

Diagnosing pediatric idiopathic cardiomyopathy is challenging due to unknown causes, complicating treatment. Developing targeted therapies requires pediatric-specific research and precision medicine approaches for better outcomes.

Area of Science:

  • Pediatric Cardiology
  • Genetics
  • Metabolic Disorders

Background:

  • Idiopathic cardiomyopathy in children is a severe condition with high mortality.
  • Etiology is complex, often involving genetic mutations or metabolic issues, but definitive causes remain elusive.
  • Current diagnostic and treatment strategies are limited, impacting patient outcomes.

Purpose of the Study:

  • To review the limitations in identifying the etiology of pediatric idiopathic cardiomyopathy.
  • To examine how these diagnostic challenges affect the development of targeted pediatric therapies.
  • To highlight the need for improved research and treatment strategies.

Main Methods:

  • A comprehensive literature review was conducted.
  • Analysis included clinical trials, cohort studies, and specialist consensus statements.
  • Focus was on pediatric cardiomyopathy etiology, treatment, and outcomes.

Main Results:

  • Many pediatric cardiomyopathy treatments are adapted from adult studies with limited effectiveness.
  • Lack of standardized classification, insufficient pharmacologic evidence, and few pediatric trials contribute to poor prognosis.
  • Current generalized treatment practices yield suboptimal outcomes.

Conclusions:

  • Advancing pediatric cardiomyopathy care necessitates precision medicine frameworks and robust genotype-phenotype databases.
  • Development of pediatric-specific clinical trials is crucial.
  • Increased focus on pediatric research and targeted strategies is vital for improving survival and outcomes.

Keywords:
genetic mutationsgenotype-phenotype correlationidiopathic cardiomyopathypediatric cardiomyopathytranslational research

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K
Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.08:37

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.

Published on: March 3, 2021

4.9K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
479
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
426
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
174